14.78

0.27% -0.03

Day One Biopharmaceuticals Inc (DAWN)

Overview News Price History Option Chain Financials Discussions Forecast

Day One Biopharmaceuticals Inc stock is traded at $14.78, with a volume of 354.24K. It is down -0.27% in the last 24 hours and up +4.75% over the past month. Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.

Previous Close:

$14.81

Open:

$14.65

24h Volume:

354.24K

Relative Volume:

0.38

Market Cap:

$1.47B

Revenue:

Net Income/Loss:

$-167.48M

P/E Ratio:

-6.4261

EPS:

-2.3

Net Cash Flow:

$-197.47M

1W Performance:

+2.93%

1M Performance:

+4.75%

6M Performance:

-13.98%

1Y Performance:

+15.75%

1-Day Range:

$14.43

$14.80

1-Week Range:

$14.03

$16.23

52-Week Range:

$10.90

$18.07

Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile

Name

Day One Biopharmaceuticals Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

650 484-0899

Address

2000 SIERRA POINT PARKWAY, SUITE 501, BRISBANE

Employee

174

Twitter

Next Earnings Date

Latest SEC Filings

DAWN's Discussions on Twitter

Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-09-24	Reiterated	Needham	Buy
Aug-01-24	Upgrade	BofA Securities	Underperform → Buy
Apr-24-24	Reiterated	Needham	Buy
Apr-25-23	Downgrade	BofA Securities	Buy → Underperform
Feb-08-23	Initiated	CapitalOne	Overweight
Feb-03-23	Initiated	Oppenheimer	Perform
Dec-15-22	Initiated	H.C. Wainwright	Buy
Dec-14-22	Initiated	Needham	Buy
Dec-05-22	Initiated	Goldman	Buy
Dec-01-22	Initiated	BofA Securities	Buy

View All

Day One Biopharmaceuticals Inc Stock (DAWN) Latest News

05:44 AM

Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Rating Upgraded by TD Cowen - MarketBeat

05:44 AM

Nov 04, 2024

Day one biopharmaceuticals head of R&D sells $8,010 in stock - Investing.com

Nov 04, 2024

Forecast: Analysts Think Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Business Prospects Have Improved Drastically - Simply Wall St

Nov 04, 2024

Bullish: Analysts Just Made A Huge Upgrade To Their Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Forecasts - Yahoo Finance

Nov 04, 2024

What is HC Wainwright's Estimate for DAWN Q1 Earnings? - MarketBeat

Nov 04, 2024

Nov 03, 2024

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Nov 03, 2024

Nov 01, 2024

We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Easily Afford To Drive Business Growth - Yahoo Finance

Nov 01, 2024

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 01, 2024

Day One Biopharmaceuticals’ Revenue at Risk: Heavy Dependence on Few Key Customers - TipRanks

Nov 01, 2024

Oct 31, 2024

(DAWN) Proactive Strategies - Stock Traders Daily

Oct 31, 2024

Day One Biopharmaceuticals (NASDAQ:DAWN) Releases Earnings Results, Beats Estimates By $0.58 EPS - MarketBeat

Oct 31, 2024

Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up After Earnings Beat - MarketBeat

Oct 31, 2024

Pre-Market Trading Boosts Day One (DAWN) Amid High OJEMDA Demand - Stocks Telegraph

Oct 31, 2024

Day One Biopharmaceuticals (NASDAQ:DAWN) Receives Buy Rating from HC Wainwright - MarketBeat

Oct 31, 2024

ChromaDex Q3 2024 Earnings Preview - MSN

Oct 31, 2024